Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DM199 for Pregnancy Complications
NCT06875141Phase 2Withdrawn
- Sponsor
- DiaMedica Therapeutics
- Start
- May 2025
- Primary completion
- May 2025
- Modality
- Replacement Enzymes
01
Overview
A Phase 2 trial of rinvecalinase alfa in preeclampsia, fetal growth restriction (FGR), sponsored by DiaMedica Therapeutics. Planned start May 2025; status: withdrawn.
02
Drugs
rinvecalinase alfa
03
Conditions
preeclampsiafetal growth restriction (FGR)
Beyond the preview
Go deeper on NCT06875141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06875141.